Skip to main content

Advertisement

SpringerLink
Log in

Genetic association between APOA1 and APOD polymorphisms and Alzheimer’s disease in a Japanese population

  • Psychiatry and Preclinical Psychiatric Studies - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Alterations in lipoproteins are involved in the pathophysiology of Alzheimer’s disease (AD). For sporadic AD, the Apolipoprotein E (APOE) is recognized as a sole genetic risk factor. Apolipoprotein A1 (APOA1) has been suggested to bind amyloid β and promoter polymorphisms of the APOA1 gene were likely to affect the onset of the disease. Apolipoprotein D (APOD) expression is upregulating in AD brain and evidences showed APOD polymorphisms affect the risk for AD. The aim of this study was to investigate whether polymorphisms of both APOA1 and APOD genes are associated with early-onset AD (EOAD) and late-onset AD (LOAD). Common single nucleotide polymorphisms (SNPs) of the two genes were analyzed using a case–control study design. There were no associations between the two SNPs of the APOA1 gene and the onset of AD. No synergetic associations were found among the APOA1 SNPs, APOE and the risk for AD. Rs7659, 3′ UTR polymorphism of the APOD gene was associated with EOAD in APOEε4 (−) subgroup. We were unable to show any impact of the other two SNPs of the APOD gene on the risk for AD. Our results suggest that the variation of the APOD gene modifies the risk for AD. Further association studies for APOD 3′ UTR polymorphisms with other ethnic groups would be needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Chen Y, Jia L, Wei C, Wang F, Lv H, Jia J (2008) Association between polymorphisms in the apolipoprotein D gene and sporadic Alzheimer’s disease. Brain Res 1233:196–202. doi:10.1016/j.brainres.2008.07.018

    Article  PubMed  CAS  Google Scholar 

  • Desai PP, Hendrie HC, Evans RM, Murrell JR, DeKosky ST, Kamboh MI (2003) Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans. Am J Med Genet B Neuropsychiatr Genet 116B(1):98–101. doi:10.1002/ajmg.b.10798

    Article  PubMed  Google Scholar 

  • Glockner F, Ohm TG (2003) Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype. Neuroscience 122(1):103–110

    Article  PubMed  CAS  Google Scholar 

  • Helbecque N, Codron V, Cottel D, Amouyel P (2008) An apolipoprotein A-I gene promoter polymorphism associated with cognitive decline, but not with Alzheimer’s disease. Dement Geriatr Cogn Disord 25(2):97–102. doi:10.1159/000112176

    Article  PubMed  CAS  Google Scholar 

  • Helisalmi S, Hiltunen M, Vepsalainen S, Iivonen S, Corder EH, Lehtovirta M, Mannermaa A, Koivisto AM, Soininen H (2004) Genetic variation in apolipoprotein D and Alzheimer’s disease. J Neurol 251(8):951–957. doi:10.1007/s00415-004-0470-8

    Article  PubMed  CAS  Google Scholar 

  • Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS (2001) Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40(12):3553–3560

    Article  PubMed  CAS  Google Scholar 

  • Lefterov I, Fitz NF, Cronican AA, Fogg A, Lefterov P, Kodali R, Wetzel R, Koldamova R (2010) Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice. J Biol Chem 285(47):36945–36957. doi:10.1074/jbc.M110.127738

    Article  PubMed  CAS  Google Scholar 

  • Lewis TL, Cao D, Lu H, Mans RA, Su YR, Jungbauer L, Linton MF, Fazio S, LaDu MJ, Li L (2010) Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem 285(47):36958–36968. doi:10.1074/jbc.M110.127829

    Article  PubMed  CAS  Google Scholar 

  • Martinez E, Navarro A, Ordonez C, Del Valle E, Tolivia J (2012) Amyloid-beta25-35 induces apolipoprotein D Synthesis and growth arrest in HT22 hippocampal cells. J Alzheimers Dis 30(2):233–244. doi:10.3233/JAD-2012-112102

    PubMed  CAS  Google Scholar 

  • Merched A, Xia Y, Visvikis S, Serot JM, Siest G (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease. Neurobiol Aging 21(1):27–30

    Article  PubMed  CAS  Google Scholar 

  • Muffat J, Walker DW, Benzer S (2008) Human APOD, an apolipoprotein up-regulated in neurodegenerative diseases, extends lifespan and increases stress resistance in Drosophila. Proc Natl Acad Sci USA 105(19):7088–7093. doi:10.1073/pnas.0800896105

    Article  PubMed  CAS  Google Scholar 

  • Navarro A, Del Valle E, Astudillo A, Gonzalez del Rey C, Tolivia J (2003) Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits. Exp Neurol 184(2):697–704. doi:10.1016/S0014-4886(03)00315-7

    Article  PubMed  CAS  Google Scholar 

  • Ordonez C, Navarro A, Perez C, Martinez E, del Valle E, Tolivia J (2012) Gender differences in apolipoprotein D expression during aging and in Alzheimer disease. Neurobiol Aging 33(2):433 e411–e420. doi:10.1016/j.neurobiolaging.2011.01.010

  • Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, Magdesian MH, Grinberg LT, Panizzutti R, Ferreira ST (2009) Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol 41(6):1361–1370. doi:10.1016/j.biocel.2008.12.003

    Article  PubMed  CAS  Google Scholar 

  • Smach MA, Edziri H, Charfeddine B, Ben Othman L, Lammouchi T, Ltaief A, Nafati S, Dridi H, Bennamou S, Limem K (2011) Polymorphism in APOA1 Influences high-density lipoprotein cholesterol levels but is not a major risk factor of Alzheimer’s disease. Dement Geriatr Cogn Dis Extra 1(1):249–257. doi:10.1159/000329910

    Article  PubMed  Google Scholar 

  • Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, Lux O, Brodaty H, Mather K, Smythe GA, Sachdev PS (2012) Plasma apolipoprotein levels are associated with cognitive status and decline in a community cohort of older individuals. PLoS ONE 7(6):e34078. doi:10.1371/journal.pone.0034078

    Article  PubMed  CAS  Google Scholar 

  • Thomas EA, Laws SM, Sutcliffe JG, Harper C, Dean B, McClean C, Masters C, Lautenschlager N, Gandy SE, Martins RN (2003) Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer’s disease: no relation to apolipoprotein E expression or genotype. Biol Psychiatry 54(2):136–141

    Article  PubMed  CAS  Google Scholar 

  • Vollbach H, Heun R, Morris CM, Edwardson JA, McKeith IG, Jessen F, Schulz A, Maier W, Kolsch H (2005) APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann Neurol 58(3):436–441. doi:10.1002/ana.20593

    Article  PubMed  CAS  Google Scholar 

  • Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet 337(8750):1158–1159

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was partially supported by the High Technology Research Center Grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan and Sportology Center, Juntendo University Graduate School of Medicine. We are grateful for the technical assistance of Ms. K. Yamamoto. We have no potential conflicts.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan

    Nobuto Shibata, Tohru Ohnuma, Hiromi Shimazaki, Miwa Komatsu, Bolati Kuerban, Katrin Tomson & Heii Arai

  2. Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan

    Tomoyuki Nagata, Shunichiro Shinagawa & Kazuhiko Nakayama

  3. Doctoral School of Behavioural, Social and Health Sciences, University of Tartu, Tartu, Estonia

    Katrin Tomson

  4. Division of Molecular Genetics, Institute of DNA Medicine, Jikei University School of Medicine, Tokyo, Japan

    Hisashi Yamada

Authors
  1. Nobuto Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoyuki Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shunichiro Shinagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tohru Ohnuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiromi Shimazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Miwa Komatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bolati Kuerban
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Katrin Tomson
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kazuhiko Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hisashi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Heii Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nobuto Shibata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shibata, N., Nagata, T., Shinagawa, S. et al. Genetic association between APOA1 and APOD polymorphisms and Alzheimer’s disease in a Japanese population. J Neural Transm 120, 1599–1603 (2013). https://doi.org/10.1007/s00702-013-1036-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-013-1036-7

Keywords

Search

Navigation